DNMT1 and glioblastoma: Preclinical evidence: In GBM cell lines, decitabine has been shown to induce expression of endogenous retroviral elements, thereby stimulating an interferon response that can attract immune cells (a phenomenon exploited in trials combining DNMT inhibitors with immunotherapy) (Lofiego et al., 2024).